期刊文献+

液质联用法同时测定人血浆氯吡格雷活性和非活性代谢物浓度 被引量:1

下载PDF
导出
摘要 目的建立快速测定人血浆中氯吡格雷活性和非活性代谢物浓度的LC-MS/MS法。方法乙醚液液萃取法,采用Acquity UPLC BEH C18色谱柱。以正离子多反应离子监测方式进行检测。结果氯吡格雷羧酸代谢物、卡马西平、氯吡格雷活性代谢物衍生物分离良好,氯吡格雷羧酸代谢物的线性范围良好。两种代谢产物日内、日间RSD小于12%。在不同贮存条件下代谢物稳定性良好。结论该方法操作简便快速,重复性好,灵敏度高,适用于氯吡格雷代谢产物血药浓度的测定。
出处 《海峡药学》 2017年第11期46-48,共3页 Strait Pharmaceutical Journal
基金 福建省卫生厅青年科研基金(2015-1-49)
  • 相关文献

参考文献6

二级参考文献120

  • 1郝盼盼,陈玉国,张运.氯吡格雷抵抗相关因素的研究进展[J].心血管病学进展,2009,30(6):991-994. 被引量:21
  • 2Geiger J, Brich J, Liedl P, et al. Specific impairment of human platelet P2Y(AC) ADP receptor mediated signaling by the antiplatelet drug clopidogrel [ J]. Arterioscler Thromb Vasc Biol, 1999 ; 19:2007 -2011.
  • 3Robinson A, Hillis J, Neal C, et al. The validation of a bioanalytical method for the determination of clopidogrel in human plasma[ J]. Chromatogr B, 2007 ;848:344 - 354.
  • 4Nirogi RVS, Kandikere VN, Shukla M, et al. Quantification of clopidogrel in human plasmaby sensitive liquid chromatography/tandem mass spectrometry [ J ]. Rapid Commun Mass Spectrom, 2006 ; 20 : 1695 - 1700.
  • 5Beom SS, Sun DY. Determination of clopidogrel in human plasma by liquidchromatography/tandem mass spectrometry: application to a clinical pharmacokinetic study [ J ]. Biomed Chromatogr, 2007 ; 21 : 883 - 889.
  • 6King SB, Snfith SC Jr, Hirshfdd JW Jr, et al. 2007 Focused Update of ACC,/AHA/SCAI 2005 Guideline Update for Penmtaneous Coronary Intervention: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guiddines:2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Pereutaneons Coronary Intervention,Wrlting on Behalf of the 2005 Writing Committee[J]. Circulation,2008,117(2) : 261.
  • 7Kyle JE, George AS, Howant LM,et al. Clopidogrel pharmacogeneties and risk of inadequate platelet inhibition: US FDA recommendations[ J]. Pharmacogenomics, 2009, 10( 11 ) : 1799.
  • 8FDA Drug Safety Communicatice: Reduced effectiveness of Plavix (clopidogrel) in patients who ave poor metabolizers of the drug. http://www, fda. gov/Druga/DmgSdety/Postmarket Drug Safetylnfor- mationforPatients and Providvrs/ucm.203888. htm. [ 2010 - 03 - 12].
  • 9Umemura K, Furuta T, Kondo K. The common gene variations of CYP2C19 affect pharmacokinetic and phannacodynamic in an active metabolite of dopidogrel in healthy subjects[ J]. J Thromb Haemost, 2008,6(8) : 1439.
  • 10Kim KA,Park PW,Hong SJ,et al.The effect of CYP2C19 polymorphism on pharmaeokinetic and phannacodynamic of dopidogxel: a possible mechanism for clopidogrel resistance[J]. Clin Pharmacol Ther, 2008, 84 (2) :236.

共引文献54

同被引文献15

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部